866-997-4948(US-Canada Toll Free)

Psoriasis - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Pharmaceutical

No. of Pages : 648 Pages

Psoriasis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis Pipeline Review, H1 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 21, 44, 42, 1, 103, 32 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 8
Psoriasis - Overview 9
Psoriasis - Therapeutics Development 10
Psoriasis - Therapeutics Assessment 39
Psoriasis - Companies Involved in Therapeutics Development 55
Psoriasis - Drug Profiles 130
Psoriasis - Discontinued Products 607
Psoriasis - Product Development Milestones 610
Appendix 619

List of Tables
Number of Products under Development for Psoriasis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Psoriasis - Pipeline by 3SBio Inc, H1 2017
Psoriasis - Pipeline by AbbVie Inc, H1 2017
Psoriasis - Pipeline by Abeome Corp, H1 2017
Psoriasis - Pipeline by AbGenomics International Inc, H1 2017
Psoriasis - Pipeline by Addex Therapeutics Ltd, H1 2017
Psoriasis - Pipeline by Adello Biologics LLC, H1 2017
Psoriasis - Pipeline by Advinus Therapeutics Ltd, H1 2017
Psoriasis - Pipeline by Affibody AB, H1 2017
Psoriasis - Pipeline by Albireo Pharma Inc, H1 2017
Psoriasis - Pipeline by Alfacyte Ltd, H1 2017
Psoriasis - Pipeline by Allergan Plc, H1 2017
Psoriasis - Pipeline by Almirall SA, H1 2017
Psoriasis - Pipeline by Alteogen Inc, H1 2017
Psoriasis - Pipeline by Alvotech Iceland, H1 2017
Psoriasis - Pipeline by Amgen Inc, H1 2017
Psoriasis - Pipeline by Anacor Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by AnaptysBio Inc, H1 2017
Psoriasis - Pipeline by ApoPharma Inc, H1 2017
Psoriasis - Pipeline by Arbor Pharmaceuticals LLC, H1 2017
Psoriasis - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by Argos Therapeutics Inc, H1 2017
Psoriasis - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Psoriasis - Pipeline by AstraZeneca Plc, H1 2017
Psoriasis - Pipeline by Athenex Inc, H1 2017
Psoriasis - Pipeline by Atlantic Bio Sci LLC, H1 2017
Psoriasis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by Bayer AG, H1 2017
Psoriasis - Pipeline by Beta Pharma Inc, H1 2017
Psoriasis - Pipeline by BioApex sro, H1 2017
Psoriasis - Pipeline by Biocad, H1 2017
Psoriasis - Pipeline by Biocon Ltd, H1 2017
Psoriasis - Pipeline by BioLingus AG, H1 2017
Psoriasis - Pipeline by BioMAS Ltd, H1 2017
Psoriasis - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
Psoriasis - Pipeline by Bionomics Ltd, H1 2017
Psoriasis - Pipeline by Bionovis SA, H1 2017
Psoriasis - Pipeline by BirchBioMed Inc, H1 2017
Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Psoriasis - Pipeline by Brickell Biotech Inc, H1 2017
Psoriasis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Psoriasis - Pipeline by C4X Discovery Holdings PLC, H1 2017
Psoriasis - Pipeline by CalciMedica Inc, H1 2017
Psoriasis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Psoriasis - Pipeline by Celgene Corp, H1 2017
Psoriasis - Pipeline by Cell Medica Ltd, H1 2017
Psoriasis - Pipeline by Cellceutix Corp, H1 2017
Psoriasis - Pipeline by ChemoCentryx Inc, H1 2017
Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Psoriasis - Pipeline by ChironWells GmbH, H1 2017
Psoriasis - Pipeline by Coherus BioSciences Inc, H1 2017
Psoriasis - Pipeline by Compugen Ltd, H1 2017
Psoriasis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017
Psoriasis - Pipeline by Crescita Therapeutics Inc, H1 2017
Psoriasis - Pipeline by CritiTech Inc, H1 2017
Psoriasis - Pipeline by Curapel Ltd, H1 2017
Psoriasis - Pipeline by Dermala Inc, H1 2017
Psoriasis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
Psoriasis - Pipeline by DURECT Corp, H1 2017
Psoriasis - Pipeline by EA Pharma Co Ltd, H1 2017
Psoriasis - Pipeline by Eli Lilly and Company, H1 2017
Psoriasis - Pipeline by ELORAC Inc, H1 2017
Psoriasis - Pipeline by Exicure Inc, H1 2017
Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Psoriasis - Pipeline by Forward Pharma A/S, H1 2017
Psoriasis - Pipeline by Galapagos NV, H1 2017
Psoriasis - Pipeline by Galderma SA, H1 2017
Psoriasis - Pipeline by Galectin Therapeutics Inc, H1 2017
Psoriasis - Pipeline by Gem Pharmaceuticals LLC, H1 2017
Psoriasis - Pipeline by Genentech Inc, H1 2017
Psoriasis - Pipeline by Genor BioPharma Co Ltd, H1 2017
Psoriasis - Pipeline by GlaxoSmithKline Plc, H1 2017
Psoriasis - Pipeline by GlycoMar Ltd, H1 2017
Psoriasis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
Psoriasis - Pipeline by HitGen LTD, H1 2017
Psoriasis - Pipeline by Huabo Biopharm Co Ltd, H1 2017
Psoriasis - Pipeline by Hydra Biosciences Inc, H1 2017
Psoriasis - Pipeline by iCo Therapeutics Inc., H1 2017
Psoriasis - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by Immune Response BioPharma Inc, H1 2017
Psoriasis - Pipeline by Immungenetics AG, H1 2017
Psoriasis - Pipeline by Immunwork Inc, H1 2017
Psoriasis - Pipeline by Japan Tobacco Inc, H1 2017
Psoriasis - Pipeline by Jenrin Discovery Inc, H1 2017
Psoriasis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Psoriasis - Pipeline by Johnson & Johnson, H1 2017
Psoriasis - Pipeline by Kadmon Corp LLC, H1 2017
Psoriasis - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
Psoriasis - Pipeline by KPI Therapeutics Inc, H1 2017
Psoriasis - Pipeline by Lead Pharma Holding BV, H1 2017
Psoriasis - Pipeline by LEO Pharma A/S, H1 2017
Psoriasis - Pipeline by Lupin Ltd, H1 2017
Psoriasis - Pipeline by Lycera Corp, H1 2017
Psoriasis - Pipeline by mAbxience SA, H1 2017
Psoriasis - Pipeline by Maruho Co Ltd, H1 2017
Psoriasis - Pipeline by Medestea Research & Production SpA, H1 2017
Psoriasis - Pipeline by MediGene AG, H1 2017
Psoriasis - Pipeline by Merck KGaA, H1 2017
Psoriasis - Pipeline by MetrioPharm AG, H1 2017
Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Psoriasis - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by Mycenax Biotech Inc, H1 2017
Psoriasis - Pipeline by Nimbus Therapeutics LLC, H1 2017
Psoriasis - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
Psoriasis - Pipeline by Novan Inc, H1 2017
Psoriasis - Pipeline by Novartis AG, H1 2017
Psoriasis - Pipeline by Nuevolution AB, H1 2017
Psoriasis - Pipeline by Numab Innovation AG, H1 2017
Psoriasis - Pipeline by Oncobiologics Inc, H1 2017
Psoriasis - Pipeline by OSE Immunotherapeutics, H1 2017
Psoriasis - Pipeline by Panacea Biotec Ltd, H1 2017
Psoriasis - Pipeline by Pfizer Inc, H1 2017
Psoriasis - Pipeline by Pharis Biotec GmbH, H1 2017
Psoriasis - Pipeline by Pharmedartis GmbH, H1 2017
Psoriasis - Pipeline by Philogen SpA, H1 2017
Psoriasis - Pipeline by PinCell srl, H1 2017
Psoriasis - Pipeline by Principia Biopharma Inc, H1 2017
Psoriasis - Pipeline by Promius Pharma LLC, H1 2017
Psoriasis - Pipeline by Protalix BioTherapeutics Inc, H1 2017
Psoriasis - Pipeline by Prothena Corp Plc, H1 2017
Psoriasis - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2017
Psoriasis - Pipeline by RedHill Biopharma Ltd, H1 2017
Psoriasis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
Psoriasis - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017
Psoriasis - Pipeline by Samumed LLC, H1 2017
Psoriasis - Pipeline by Sandoz International GmbH, H1 2017
Psoriasis - Pipeline by Sareum Holdings Plc, H1 2017
Psoriasis - Pipeline by SBI Biotech Co Ltd, H1 2017
Psoriasis - Pipeline by Shulov Innovative Science Ltd, H1 2017
Psoriasis - Pipeline by Sigmoid Pharma Ltd, H1 2017
Psoriasis - Pipeline by Soligenix Inc, H1 2017
Psoriasis - Pipeline by Spherium Biomed SL, H1 2017
Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017
Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Psoriasis - Pipeline by SWITCH Biotech LLC, H1 2017
Psoriasis - Pipeline by Syntrix Biosystems Inc, H1 2017
Psoriasis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Psoriasis - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Psoriasis - Pipeline by TheraMAB LLC, H1 2017
Psoriasis - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
Psoriasis - Pipeline by UCB SA, H1 2017
Psoriasis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Psoriasis - Pipeline by vTv Therapeutics Inc, H1 2017
Psoriasis - Pipeline by Wellstat Therapeutics Corp, H1 2017
Psoriasis - Pipeline by XBiotech Inc, H1 2017
Psoriasis - Pipeline by Yuhan Corp, H1 2017
Psoriasis - Dormant Projects, H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..3), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..4), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..5), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..6), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..7), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..8), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..9), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..10), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..11), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..12), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..13), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..14), H1 2017
Psoriasis - Dormant Projects, H1 2017 (Contd..15), H1 2017
Psoriasis - Discontinued Products, H1 2017
Psoriasis - Discontinued Products, H1 2017 (Contd..1), H1 2017
Psoriasis - Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures
Number of Products under Development for Acromegaly, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *